0
Catégories
Documents disponibles dans cette catégorie (251)
Ajouter le résultat dans votre panier Affiner la recherche
Trends in current electronic cigarette use among youths by age, sex, and race and ethnicity / Delvon, T. Mattingly (2024)
Titre : Trends in current electronic cigarette use among youths by age, sex, and race and ethnicity Type de document : document électronique Auteurs : Delvon, T. Mattingly, Auteur ; Joy, L. Hart, Auteur Editeur : American Medical Association (AMA) Année de publication : 2024 Collection : JAMA Internal Medicine num. 7:2 Importance : 5 p. Présentation : graph., tab. Langues : Anglais (eng) Catégories : [DIVERS] personne:par âge:jeune
[TABAC] CANDIDATS:e-cigarette
[TABAC] étude
[TABAC] tabagisme:tabagisme actifIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Electronic cigarettes (e-cigarettes) are the most used tobacco products among youths in the US and may facilitate progression into use of more harmful products, such as cigarettes, which are associated with premature morbidity and mortality. Although previous research has characterized youth e-cigarette prevalence, updated descriptive statistics on use trends by key sociodemographic characteristics are needed. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10198 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke / James L. Pirkle (2006)
Titre : Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke : 1988–2002 Type de document : texte imprimé Auteurs : James L. Pirkle, Auteur ; John T. Bernert, Auteur ; Samuel P. Caudill, Auteur ; Connie S. Sosnoff, Auteur Editeur : National Institute of Environmental Health Sciences Année de publication : 2006 Collection : Environmental health perspectives, ISSN 0091-6765 num. 114:6 Importance : p. 853-858 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Amérique:Amérique du Nord:Etats-Unis
[TABAC] chimie du tabac:fumée
[TABAC] étude
[TABAC] tabagisme:évaluation du tabagisme:marqueur
[TABAC] tabagisme:tabagisme passif:tabagisme environnementalIndex. décimale : TA 7.1 Généralités Résumé : The objective of this study was to describe the exposure of nonsmokers in the U.S. population to secondhand smoke (SHS) using serum cotinine concentrations measured over a period of 14 years, from October 1988 through December 2002. This study consists of a series of National Health and Nutrition Examination Surveys (NHANES) measuring serum cotinine as an index of SHS exposure of participants. Study participants were individuals representative of the U.S. civilian, noninstitutionalized population, ≥ 4 years of age. We analyzed serum cotinine and interview data from NHANES obtained during surveys conducted during four distinct time periods. Our results document a substantial decline of approximately 70% in serum cotinine concentrations in non-smokers during this period. This decrease was reflected in all groups within the population regardless of age, sex, or race/ethnicity. The large decrease that we observed in serum cotinine concentrations suggests a substantial reduction in the exposure of the U.S. population to SHS during the 1990s. The exposure of nonsmokers to SHS represents an important public health concern. Our findings suggest that recent public health efforts to reduce such exposures have had an important effect, although children and non-Hispanic black nonsmokers show relatively higher levels of serum cotinine. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8113 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005669 TA 7.1 PIR T Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Tumeurs de la vessie / Martine Versonne (2000)
Titre : Tumeurs de la vessie : la mauvaise influence du tabac Type de document : texte imprimé Auteurs : Martine Versonne, Auteur Editeur : Bruxelles : Actuamedica Année de publication : 2000 Collection : Le Journal du Médecin num. 1257 Importance : p.14 Langues : Français (fre) Catégories : [TABAC] étude
[TABAC] tabagisme:pathologie:cancer:cancer de la vessie
[TABAC] tabagisme:risque
[TABAC] tabagisme:tabagisme actif
[TABAC] tabagisme:tabagisme passifIndex. décimale : TA 3.2.2.6 Effets métaboliques et biologiques Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9204 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Use of electronic cigarettes (vapourisers) among adults in Great Britain / Action on Smoking and Health (2016)
Titre : Use of electronic cigarettes (vapourisers) among adults in Great Britain Type de document : document électronique Auteurs : Action on Smoking and Health, Auteur Editeur : Action on smoking and health (ASH) Année de publication : 2016 Importance : 13 p. Présentation : tab., graph. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Europe:Europe occidentale:Royaume-Uni
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude
[TABAC] sevrage tabagique
[TABAC] tabagisme:risque
[TABAC] tabagisme:tabagisme actifMots-clés : croyance Index. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : An estimated 2.8 million adults in Great Britain currently use electronic cigarettes (vape) up from only 700,000 in 2012, the first year ASH collected figures (see table 1 below).1 • Users are fairly evenly divided between smokers (1.4 million) and ex-smokers (1.3 million). The proportion of ex-smokers has increased, in 2014 two thirds of current vapers were smokers and one third ex-smokers. • The main reason given by ex-smokers who are currently vaping is to help them stop smoking while for current smokers the main reason is to reduce the amount they smoke. • Perceptions of harm from electronic cigarettes have grown with only 15% of the public accurately believing in 2016 that electronic cigarettes are a lot less harmful than smoking. The lowest level than at any time in the history of the Smokefree Britain survey. • Only 9% of vapers are using an e-liquid containing over 19 mg/ml (the limit in the Tobacco Products Directive is 20mg/ml) while 77% of vapers report using e-liquids containing 18 mg/ml of nicotine or less. • Among daily vapers only 11% report using more than 4ml of e-liquid a day. Under the Tobacco Products Directive the new limit for tank sizes is 2ml while the size limit for bottles is 10ml. The vast majority (72%) are using 4ml or less of e-liquid a day. En ligne : https://ash.org.uk/uploads/Use-of-e-cigarettes-vapes-among-adults-in-Great-Brita [...] Format de la ressource électronique : Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9572 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Use of varenicline versus bupropion and risk of psychiatric adverse events / Björn Pasternak (2013)
Titre : Use of varenicline versus bupropion and risk of psychiatric adverse events Type de document : texte imprimé Auteurs : Björn Pasternak, Auteur ; Henrik Svanström, Auteur ; Anders Hviid, Auteur Année de publication : 2013 Importance : 8 p. Langues : Anglais (eng) Catégories : [DIVERS] discipline médicale, paramédicale et scientifique:médecine:médecine spécialisée:psychiatrie
[TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.2 Autres produits Résumé : Abstract
AIM:
To investigate whether varenicline use was associated with increased risk of psychiatric adverse events, compared with bupropion, another drug used for smoking cessation.
DESIGN, SETTING AND PARTICIPANTS:
We conducted a registry-based cohort study in Denmark, 2007-10, comparing new users of varenicline and bupropion in unmatched and 1 : 1 propensity score-matched analyses.
MEASUREMENTS:
Using Cox regression, we estimated the hazard ratio (HR) of any psychiatric adverse event (emergency department visit or in-patient admission with a psychiatric diagnosis) within 30 days following treatment initiation. The unmatched and matched analyses correspond to conventional crude and fully adjusted analyses, respectively.
FINDINGS:
In unmatched analyses, there were 106 (0.18%) psychiatric adverse events among 59 790 varenicline users (rate 22 events per 1000 person-years), compared with 46 (0.26%) events among 17 936 bupropion users (rate 31 per 1000); the HR was 0.69 [95% confidence interval (CI): 0.49-0.98]. In propensity score-matched analyses, 39 (0.22%) events occurred among 17 935 varenicline users (rate 27 per 1000), compared with 46 (0.26%) events among 17 935 bupropion users (rate 31 per 1000); varenicline was not associated with increased risk of psychiatric adverse events (HR 0.85, 95% CI: 0.55-1.30). The overall rate of psychiatric adverse events was substantially higher among participants with a history of psychiatric disorder than in patients without such history; the risk associated with varenicline did not differ significantly by history of psychiatric disorder.
CONCLUSIONS:
In Denmark, the risk of psychiatric adverse events diagnosed during an emergency department visit or in-patient admission was not significantly higher with varenicline use compared with bupropion.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8040 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005590 TA 6.2.3.2 PAS U Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Les vapoteurs quotidiens doubleraient leur risque de crise cardiaque / Metro (2018-08-31)
Titre : Les vapoteurs quotidiens doubleraient leur risque de crise cardiaque Type de document : document électronique Auteurs : Metro, Auteur Editeur : Rossel Année de publication : 2018-08-31 Importance : 1 p. Langues : Français (fre) Catégories : [DIVERS] géographie:Amérique:Amérique du Nord:Etats-Unis
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude
[TABAC] tabagisme:risque:risque cardiovasculaireIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8979 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline, an alpha-4-beta-2(α4β2) nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation / David H. Gonzales (01/06/2006)
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline and bupropion sustained-release combination therapy for smoking cessation / Jon O. Ebbert (2009)
Titre : Varenicline and bupropion sustained-release combination therapy for smoking cessation Type de document : texte imprimé Auteurs : Jon O. Ebbert, Auteur ; Ivana T. Croghan, Auteur ; Amit Sood, Auteur Editeur : Oxford University Press Année de publication : 2009 Collection : Nicotine and Tobacco Research num. Vol 11, n.3 Importance : p. 234-239 Présentation : tad., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract
INTRODUCTION:
Varenicline and bupropion sustained release (SR) are both safe and effective for the treatment of tobacco dependence and have different mechanisms of action. Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with single-agent therapy.
METHODS:
We enrolled cigarettes smokers in an open-label, one-arm, Phase II clinical trial to obtain preliminary data on the potential effectiveness and safety of combination therapy with varenicline and bupropion SR for the treatment of tobacco dependence. Eligible subjects received varenicline titrated to 1.0 mg by mouth twice daily and bupropion SR titrated to 150 mg by mouth twice daily for a total of 12 weeks along with behavioral therapy. Self-reported smoking abstinence was biochemically confirmed with expired carbon monoxide. A total of 38 smokers with a mean age of 49.1 years (SD = 12.4) who smoked an average of 19.9 cigarettes/day (SD = 7.8) for 30 years (SD = 12.3) were enrolled.
RESULTS:
Seven-day point-prevalent smoking abstinence rates were 71% (95% CI = 54%-85%) at 3 months and 58% (95% CI = 41%-74%) at 6 months. Mean weight change during the medication phase among smoking-abstinent subjects was 1.6 kg (SD = 2.4). For both medications, 74% of subjects took at least 90% of the prescribed doses. The most common side effects were sleep disturbance (26%) and nausea (24%). No increase in depressive symptoms was observed, and no subjects reported suicidal ideation.
DISCUSSION:
Combination therapy with varenicline and bupropion SR may be effective for increasing smoking abstinence rates above that observed with monotherapy.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7947 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005488 TA 6.2.3.1.4 EBB V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Varenicline for smoking cessation : is it a heartbreaker? Type de document : texte imprimé Auteurs : J. Taylor Hays, Auteur Editeur : Canadian medical association Année de publication : 2011 Collection : Canadian medical association journal, ISSN 0008-4409 Importance : 2 p. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:pathologie:pathologie cardio-vasculaireIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Risk of serious adverse cardiovascular events associated wirh varenicline a systematic review and meta-analysis En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168613/ Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7949 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline has antidepressant-like in activity in the forced swim test augments sertraline's effect / Hans Rollema (2009)
Titre : Varenicline has antidepressant-like in activity in the forced swim test augments sertraline's effect Type de document : texte imprimé Auteurs : Hans Rollema, Auteur ; Victor Guanowsky, Auteur ; Yann S. Mineur, Auteur Editeur : Elsevier Science Direct Année de publication : 2009 Collection : European Journal of Pharmacology, ISSN 0014-2999 num. Vol 605 Importance : p. 114-116 Présentation : graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist developed as a smoking cessation aid, showed antidepressant-like activity in the forced swim test in two mouse strains. In addition, a low varenicline dose significantly enhanced the effects of moderately active doses of the selective serotonin reuptake inhibitor sertraline. These findings are consistent with the notion that reducing alpha4beta2 nicotinic acetylcholine receptor activity either by antagonists or by partial agonists that can partially activate or desensitize acetylcholine receptors is associated with antidepressant-like properties. These data suggest that varenicline may have antidepressant potential and can, when combined, augment antidepressant responses of selective serotonin reuptake inhibitors. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7946 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005487 TA 6.2.3.1.4 ROL V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline / Gillian M. Keating (2010)
Titre : Varenicline : a pharmacoeconimic review of its use as an aid to smoking cessation Type de document : texte imprimé Auteurs : Gillian M. Keating, Auteur ; Katherine, A. Lyseng-Williamson, Auteur Année de publication : 2010 Importance : 19 p. Présentation : tab. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:aspect économique:coût du tabagisme:coût pour le fumeurIndex. décimale : TA 6.2.3.2 Autres produits Résumé : Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Well designed clinical trials indicate that varenicline is an effective aid to smoking cessation. During the last 4 weeks of treatment, carbon monoxide-confirmed continuous abstinence rates were generally significantly higher with varenicline than with placebo, bupropion sustained release (SR) or nicotine replacement therapy. Varenicline also reduced cravings, the reinforcing effects of smoking and some withdrawal symptoms. Another well designed trial demonstrated that extending varenicline therapy by an additional 12 weeks helped maintain abstinence in individuals who had quit smoking. Varenicline was generally well tolerated in clinical trials; nausea, the most commonly occurring adverse event, diminished over time. More data are needed regarding the potential for neuropsychiatric events in varenicline recipients. Some of these events may be associated with nicotine withdrawal, rather than varenicline, although neuropsychiatric events have been observed in individuals who continued to smoke whilst receiving varenicline. In modelled cost-effectiveness analyses based on data from clinical trials in participants receiving smoking cessation therapy, 12 weeks' treatment with varenicline was predicted to be cost effective from a healthcare payer perspective in numerous countries. With regard to the incremental costs per QALY or life-year gained, 12 weeks' treatment with varenicline consistently dominated bupropion SR and nicotine replacement therapy and was dominant over or considered cost effective relative to unaided cessation, regular brief counselling or nortriptyline in analyses based on Markov models. In additional modelled analyses from a healthcare payer perspective, administering varenicline for an additional 12 weeks in participants who had successfully quit smoking was estimated to have acceptable incremental costs per QALY gained relative to varenicline for 12 weeks and to dominate other smoking cessation options. Moreover, in Swedish analyses that also included societal costs for production and consumption, the incremental cost per QALY gained for varenicline versus bupropion SR, and for an additional 12 weeks of varenicline therapy versus varenicline for 12 weeks only, was below commonly accepted thresholds of cost effectiveness. A US decision-analytic model from the perspective of various US health insurance plans demonstrated that, after 2 years, varenicline was predicted to dominate bupropion SR, in terms of the incremental cost per additional smoking cessation. Varenicline was also dominant or cost effective versus nicotine replacement therapy, and cost effective versus unaided cessation. Sensitivity analyses demonstrated that the results of cost-effectiveness studies were generally robust to plausible variations in key parameters. In conclusion, varenicline is an effective aid to smoking cessation. Varenicline was generally well tolerated in clinical trials, although more data are needed regarding the potential for neuropsychiatric events. The costs associated with varenicline are offset by direct savings associated with the reduction in smoking-related diseases. Despite their limitations, available pharmacoeconomic analyses from numerous countries support the use of varenicline for 12 or 24 weeks as a cost-effective treatment relative to other smoking cessation therapies in smokers who wish to quit smoking. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8041 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005591 TA 6.2.3.2 KEA V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Varenicline versus transdermal nicotine patch for smoking cessation : results from a randomised, open-label trial Type de document : texte imprimé Auteurs : Henri-Jean Aubin, Auteur ; Alex Bobak, Auteur ; John Britton, Auteur Editeur : Thorax Année de publication : 08/02/2008 Collection : Thorax Importance : 8 p. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:efficacité du sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : La varénicline, un nouveau traitement pour la cessation tabagique, a démontré de manière significative une plus grande efficacité sur le placebo et le bupropion. Une étude a été menée pour comparer un régime de 12 semaines à la varénicline en parallèle avec un régime de 10 semaines d'une thérapie de remplacement nicotinique transcutanée standard pour le sevrage tabagique. En ligne : https://thorax.bmj.com/content/63/8/717.long Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=3011 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Virtual reality cue exposure for the relapse prevention of tobacco consumption / Camille Giovancarli (2016)
Titre : Virtual reality cue exposure for the relapse prevention of tobacco consumption : a study protocol for a randomized controlled trial Type de document : document électronique Auteurs : Camille Giovancarli, Auteur ; Eric Malbos, Auteur ; Karine Baumstarck, Auteur Editeur : Springer Année de publication : 2016 Collection : Trials, ISSN 1745-6215 num. 17 Importance : 9 p. Présentation : tab., ill. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique
[TABAC] sevrage tabagique:efficacité du sevrage:rechute
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique:thérapie cognitivo-comportementale
[TABAC] tabagisme:aspect psychologique:comportementMots-clés : réalité virtuelle. Index. décimale : TA 6.5 Rechutes Résumé : Background:
Successful interventions have been developed for smoking cessation, but the success of smoking relapse prevention interventions has been limited. In particular, cognitive behavioural therapy (CBT) has been hampered by a high relapse rate. Because relapses can be due to the presence of conditions associated with tobacco consumption (such as drinking in bars with friends), virtual reality exposure therapy (VRET) can generate synthetic environments that represent risk situations for the patient in the context of relapse prevention. The primary objective of this study is to evaluate the effectiveness of CBT coupled with VRET, in comparison to CBT alone, in the prevention of smoking relapse. The secondary objectives are to assess the impact of CBT coupled with VRET on anxiety, depression, quality of life, self-esteem and addictive comorbidities (such as alcohol, cannabis, and gambling). A third objective examines the feasibility and acceptability of VR use considering elements such as presence, cybersickness and number of patients who complete the VRET program.
Method/design:
The present study is a 14-month (2 months of therapy followed by 12 months of follow-up), prospective, comparative, randomized and open clinical trial, involving two parallel groups (CBT coupled with VRET versus CBT alone). The primary outcome is the proportion of individuals with tobacco abstinence at 6 months
after the end of the therapy. Abstinence is defined by the total absence of tobacco consumption assessed during a post-test interview and with an apparatus that measures the carbon monoxide levels expired. A total of 60 individuals per group will be included.
Discussion :
This study is the first to examine the efficacy of CBT coupled with VRET in the prevention of smoking relapse. Because VRET is simple to use and has a low cost, this interactive therapeutic method might be easily implemented in clinical practice if the study confirms its efficacyEn ligne : https://doi.org/10.1186/s13063-016-1224-5 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9756 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : When smokers move out and non-smokers move in : residential thirdhand smoke pollution and exposure Type de document : texte imprimé Auteurs : Georg E. Matt, Auteur ; Penelope J. E. Quintana, Auteur ; Joy M. Zakarian, Auteur ; Addie L. Fortmann, Auteur Editeur : BMJ Publishing Group Année de publication : 2011 Collection : Tobacco Control num. 20 Importance : 8 p. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] tabagisme:effet sur l'environnement:pollution
[TABAC] tabagisme:effet sur l'environnement:tabagie
[TABAC] tabagisme:tabagisme passifIndex. décimale : TA 7.9 Fumée tertiaire Résumé : Abstract
Background This study examined whether thirdhand smoke (THS) persists in smokers' homes after they move out and non-smokers move in, and whether new non-smoking residents are exposed to THS in these homes.
Methods The homes of 100 smokers and 50 non-smokers were visited before the residents moved out. Dust, surfaces, air and participants' fingers were measured for nicotine and children's urine samples were analysed for cotinine. The new residents who moved into these homes were recruited if they were non-smokers. Dust, surfaces, air and new residents' fingers were examined for nicotine in 25 former smoker and 16 former non-smoker homes. A urine sample was collected from the youngest resident.
Results Smoker homes' dust, surface and air nicotine levels decreased after the change of occupancy (p<0.001); however dust and surfaces showed higher contamination levels in former smoker homes than former non-smoker homes (p<0.05). Non-smoking participants' finger nicotine was higher in former smoker homes compared to former non-smoker homes (p<0.05). Finger nicotine levels among non-smokers living in former smoker homes were significantly correlated with dust and surface nicotine and urine cotinine.
Conclusions These findings indicate that THS accumulates in smokers' homes and persists when smokers move out even after homes remain vacant for 2 months and are cleaned and prepared for new residents. When non-smokers move into homes formerly occupied by smokers, they encounter indoor environments with THS polluted surfaces and dust. Results suggest that non-smokers living in former smoker homes are exposed to THS in dust and on surfaces.En ligne : https://tobaccocontrol.bmj.com/content/20/1/e1 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8086 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Workplace smoking / Carin Håkansta (2004)
Titre : Workplace smoking : working paper: a review of national and local practical and regulatory measures Type de document : document électronique Auteurs : Carin Håkansta, Auteur Editeur : Genève [Suisse] : International Labour Office Publications (ILO Publications) Année de publication : 2004 Importance : 89 p. Présentation : tab., graph. ISBN/ISSN/EAN : 978-92-2-115720-5 Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] législation:législation antitabac:interdiction de fumer
[TABAC] législation:milieu réglementé:lieu de travail
[TABAC] tabagisme:tabagisme passifIndex. décimale : TA 7.2 Environnement enfumé Résumé : Workplace smoking can be a serious safety and health hazard and a cause of conflict. Promotion and implementation of a smoke-free work environment therefore fall under the ILO’s mandate to create healthy and safe workplaces. This working paper, based to a large extent on an informal survey carried out by ILO SafeWork in 2003, sets out to provide an overview of attitudes, legislation and practices related to smoke-free workplaces in different parts of the world. It could serve as a background paper for further ILO tripartite discussions leading up to a new international instrument.
Because of the rapidly changing nature of the debate and legal frameworks related to workplace smoking, the overview will need to be reviewed and periodically updated. Such exercises may require pooling more examples of enterprise and trade union policies and programmes and undertaking a thorough analysis of existing legislation, policies and best practices.
The working paper has been written within the general framework of preventing psychosocial problems at work. Its purpose is to create a knowledge base for further activities in the area of promoting and implementing smoke-free workplaces and also the SOLVE interactive educational programme on psychosocial issues.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9989 Aucun avis, veuillez vous identifier pour ajouter le vôtre !